Pepaxto might not be a complete bust in myeloma.
A hit and a miss with pegcetacoplan in late-stage trials leaves Apellis with shrinking prospects.
Rilzabrutinib flunks a pivotal trial in pemphigus, but all eyes are on tolebrutinib in multiple sclerosis.
The autoimmune target CD40 has yielded few hits despite years of research, but a few companies are keeping the faith.
The clinical hold for Biomarin’s phenylketonuria project comes on the heels of an FDA adcom to discuss gene therapy toxicity.
The Danish group reports promising mid-stage data with its respiratory syncytial virus vaccine, but competition is fierce.
But mixed data and a previous failure provide reasons to be cautious.
ALXN1840 could challenge older copper chelators, but gene therapies are coming.
But is there room for another antibody, given lacklustre sales and Regeneron’s dominance?